Consensus estimates for Compass Pathways indicate a Q2 2026 loss of $0.46 per share on zero revenue, with the current stock price of $11.35 trading significantly below the average analyst target of $23.75. Investors are primarily focused on the company's rolling NDA submission for its COMP360 psilocybin therapy, which remains on track for completion by the fourth quarter of 2026.
Following a substantial capital raise earlier in the year, Compass enters the reporting period with a robust cash position of $466 million, providing a strategic runway into 2028. Analysts will be closely monitoring research and development spending as the company transitions from a clinical-stage biotech to a commercial-stage entity focused on treatment-resistant depression.